Provided are: an anti-gpNMB antibody that binds to gpNMB to act on the gpNMB and has properties including a property to remove dysfunctional microglia; and a use of the anti-gpNMB antibody. A humanized anti-gpNMB antibody according to the present invention binds specifically to at least one site in a region lying between a PMEL-CAF-like domain and a PKD domain of gpNMB.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided is a new means capable of effectively removing disease-associated cells that induce a disease in various diseases or enhances the progression of the disease. A pharmaceutical composition for removing disease-associated cells comprises an anti-gpNMB antibody or a fragment thereof or a derivative of foregoing that specifically binds to at least one site of a region from V78 to PKD domain of human gpNMB.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
In order to provide a therapeutic coil unit capable of accurately and reliably attaching a therapeutic coil of repetitive transcranial magnetic stimulation (rTMS) to a treatment site, and a transcranial magnetic stimulation device having the same, a coil holding unit (20) is provided with: a frame member having a window part (14) enabling observation of a magnetic stimulation site for attaching a coil device for transcranial magnetic stimulation; and an indicator (6) indicating the center position of the magnetic field when the coil device is attached.
Provided is a respiratory rate measurement device comprising: a patient connection unit for acquiring, from a user, biological information for detecting respiration; a conversion unit for converting the biological information detected by the patient connection unit into an electric signal; a respiration rate calculation unit for processing the converted electric signal to calculate a respiration rate; and a signal output unit that outputs the calculated respiration rate by at least one or more means among audio, a screen display, and a communication signal. The respiratory rate measurement device is characterized in that the respiratory rate calculation unit: calculates the respiration interval for individual respiration detected on the basis of the electric signal or respiratory supplementary information that includes the amplitude of the respiration waveform detected; calculates an index related to the reliability of the calculated respiratory rate, on the basis of the respiratory supplementary information; and outputs the index through the signal output unit. The respiratory rate measurement device calculates the respiratory rate, calculates an index related to the stability of respiration, and thereby makes it possible to determine that a situation is such that respiration detection is being performed in a stable manner.
A feature amount extractor extracts a feature amount representing the feature of a brain wave from the brain wave of a subject, the brain wave being measured when a magnetic stimulation is applied to the brain of the subject. A mental disorder determiner determines whether or not the subject has a predetermined mental disorder on the basis of a feature amount variation that is a differential value between a feature amount extracted from a brain wave measured immediately before the magnetic stimulation and a feature amount extracted from a brain wave measured immediately after the magnetic stimulation.
Provided are an oxygen concentrator, a control method, and a control program capable of preventing a drop in pilot pressure supplied to a pilot type solenoid valve used in at least either of the supply flow path opening/closing unit or the exhaust flow path opening/closing unit. An oxygen concentrator capable of preventing a pressure drop in both cylinders in the pressure equalization step and, as a result, preventing a drop in pilot pressure supplied to a pilot type solenoid valve used in at least either of the supply flow path opening/closing unit or the exhaust flow path opening/closing unit, as well as a pressure drop in the adsorption cylinder, by starting pressurization in advance in the already depressurized adsorption cylinder before the pressure equalization step.
A61M 16/10 - Preparation of respiratory gases or vapours
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
7.
OXYGEN ENRICHMENT DEVICE, CONTROL METHOD AND CONTROL PROGRAM
Provided are an oxygen concentrator, a control method, and a control program capable of preventing an internal pressure drop of the concentrated oxygen gas tank in order to extract concentrated oxygen gas at a predetermined flow rate. An oxygen concentrator capable of preventing a pressure drop in both cylinders in the pressure equalization step and, as a result, preventing a drop in the internal pressure of a concentrated oxygen gas tank, by starting pressurization in advance in the already depressurized adsorption cylinder before the pressure equalization step.
B01D 53/053 - Pressure swing adsorption with storage or buffer vessel
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
[Problem] To detect an abnormality of a flow path switching valve upstream of an oxygen concentration device from the waveform of a pressure sensor provided to a product tank. [Solution] An oxygen concentration device characterized by comprising a monitoring means that monitors the state of a flow path switching means by the output of a pressure sensor of a product tank, wherein a flow path switching valve abnormality is detected if a detected value of the pressure sensor at an adsorption step and/or desorption step deviates from the range of a prescribed threshold.
Provided is a transcranial magnetic stimulator capable of providing a magnetic stimulation with a required intensity inside a brain even when a current value and a voltage value applied to magnetic stimulation coils in a plurality of resonant circuits are reduced. The transcranial magnetic stimulator includes a plurality of resonant circuits for applying respective pulse currents to a plurality of magnetic stimulation coils to generate variable magnetic fields, and a power source that supplies an electric power to the plurality of resonant circuits. The plurality of resonant circuits are connected in parallel to the power source, and therefore, the plurality of magnetic stimulation coils are also connected in parallel to the power source. The plurality of magnetic stimulation coils are formed in approximately a same shape, and adjacently disposed such that directions of magnetic fluxes generated by the applied pulse currents are matched.
An object of the present invention is to provide a phototherapy device with which a light irradiation region can be accurately positioned on a treatment site. The phototherapy device according to an embodiment of the present disclosure includes a barrel, a light source which is installed inside the barrel and which emits light, a plurality of imaging units for imaging a marking arranged on a body, a deviation amount calculation unit for calculating a deviation amount between a plurality of images of the marking included in a plurality of images captured by the plurality of imaging units, an image combining unit for combining the plurality of images of the marking based on the calculated deviation amount, a target position determination unit for determining a position of a target in the combined image corresponding to an irradiation region of light from the light source, and a display unit for overlaying and displaying an image of a target on the combined image of the marking.
Provided is an oxygen supply device comprising an oxygen concentrator that separates oxygen from the air and produces oxygen-enriched gas and a pressure sensor at the oxygen supply end of the oxygen concentrator in the oxygen supply device that supplies oxygen-enriched gas to the user via a cannula, wherein: the oxygen supply device detects the oxygen supply pressure generated when oxygen is supplied to the user in a continuous flow from the oxygen supply device; the device is provided with a storage means for storing the pressure value corresponding to the set supply flow rate; the device is provided with an alarm means for notifying the user of an abnormal connection of the cannula if the detected pressure value is lower than the stored pressure value; and the device is provided with a function for mechanically detecting the presence or absence of oxygen supply rather than relying on the senses of the user and notifying the user of any abnormalities.
Provided is a noise reduction box characterized by comprising an accommodation unit that is located on the inside of an open/close door and accommodates an instrument therein, a box air inlet for bringing outside air into the noise reduction box, a box air outlet for exhausting the air inside the noise reduction box, and an exhaust air duct provided inside a housing for guiding exhaust air to the box air outlet, wherein an instrument air outlet of the accommodated instrument and an inlet of the exhaust air duct are in close contact when the open/close door is closed. That is, provided is a device that solves all the problems of achieving a size and weight reduction function, low noise, power saving, and heat exhaustion, which are desired for portable instruments.
A phototherapy apparatus 1 comprises: a tubular housing 4; a laser light source 6 which is disposed inside the housing 4 and which is configured to emit a laser beam toward a target region from a leading end of the housing; an exhaust port 12 which is provided in a lateral surface of the housing 4; and a shielding part 20 which is provided on the exterior side of the housing 4 so as to block reflected beams R that result from the laser beam unintendedly reflected within the housing 4 and that travel toward the outside through the exhaust port 12.
A61N 5/067 - Radiation therapy using light using laser light
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
14.
VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a pharmaceutically acceptable salt or a solvate thereof.
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a pharmaceutically acceptable salt or a solvate thereof.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 265/34 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61P 25/00 - Drugs for disorders of the nervous system
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has superior orexin type-2 receptor agonist activity.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
An object of the present invention is to provide a new indication for phototherapy or prevention, and to provide a new treatment or prevention device for irritable bowel syndrome. The present invention is a device for treating or preventing irritable bowel syndrome, specifically a light beam irradiation device for treating or preventing irritable bowel syndrome by performing percutaneous irradiation toward the sacral foramina on one side or both sides and the vicinity thereof.
The purpose of the present invention is to provide a medicine for promoting differentiation induction from oligodendrocyte progenitor cells to oligodendrocytes, and a medicine for promoting remyelination. The present invention is a medicine containing a vitamin D derivative represented by formula (1) or a pharmaceutically acceptable salt or solvate thereof, used in combination with an immunomodulatory substance.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided are crystals of a vitamin D derivative represented by formula (1) or crystals of a solvate of a vitamin D derivative represented by formula (1). Such crystals are useful as a pharmaceutical for promoting induction of differentiation of oligodendrocyte progenitor cells into oligodendrocytes.
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
The present invention provides: an anti-gpNMB antibody that binds to gpNMB and affects the same and that has an effect of such as removal of dysfunctional microglia; and a use application of the anti-gpNMB antibody. The anti-gpNMB antibody specifically binds to at least one site in a region from a PMEL-CAF-like domain to a PKD domain of gpNMB.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to the field of medicines, specifically relates to a CDK9 inhibitor compound represented by formula (I), and a pharmaceutically acceptable salt or isomer thereof, and also relates to a pharmaceutical composition and pharmaceutical preparation of the compound and a use thereof. X1, X2, R1, R2, R3, R6, A, L, n, and m are as defined in the description. The compound can be used in the preparation of a drug for treating or preventing CDK9-mediated related diseases.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A01K 67/027 - New or modified breeds of vertebrates
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
1212366, A, L, n, and m are as defined in the description. The compound can be used in the preparation of a drug for treating or preventing CDK9-mediated related diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.)
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.)
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 487/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains three hetero rings
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 231/20 - One oxygen atom attached in position 3 or 5
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Provided is an oxygen concentration device that can facilitate easy and secure replacement work, such as attaching and detaching the adsorption cylinder while reducing the force applied from the oxygen concentration device body to the adsorption cylinder cartridge in the direction of detaching and thus ensuring the connection with the oxygen concentration device, wherein the axis line of the gas flow direction of the adsorption cylinder intersects with either connection axis in the end part for supplying pressurized air to the adsorption cylinder or the end part for extracting oxygen from the adsorption cylinder.
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
A61M 16/10 - Preparation of respiratory gases or vapours
[Summary]
[Summary]
[Purpose] The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders.
[Summary]
[Purpose] The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders.
[Solution Means] The invention provides an antibody that participates in antigen-antibody reaction specifically with tau protein that has been phosphorylated in the vicinity of Ser413 of SEQ ID NO: 1, and a therapeutic agent or prophylactic agent for cognitive disorders comprising as an active ingredient a peptide that has been phosphorylated in the vicinity of Ser413.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
28.
ORAL INSERT, AND KIT FOR DETECTING PRESENCE OF SLEEP APNEA SYNDROME
[Problem] To provide an oral insert used in order to accurately detect the presence of sleep apnea syndrome using a negative expiratory pressure (NEP) method. [Solution] An oral insert to be inserted into the oral cavity of a user, the oral insert being characterized by having: a cylindrical base part, the base part having an air port that penetrates therethrough; and an extension part extending in the longitudinal direction from an end of the base part, the extension part having a slit in a section thereof.
A phototherapy device 1 includes a laser light source 8 for emitting laser light at a target portion T, a limit switch 10 for detecting an approach of the laser light source 8 to a target portion T up to a predetermined distance and outputting a proximity signal, and an optical sensors 7 for detecting a distance to the target portion T and outputting a distance signal S corresponding to the distance and is configured so that a reference value L0 is set based on the distance signal S detected after the proximity signal is detected and emission of laser light by the laser light source 8 is permitted in accordance with an amount of fluctuation of the distance signal S with respect to the reference value L0.
Provided are: an oxygen enrichment device that can inhibit a reduction in the internal pressure of an enriched oxygen gas tank in order to discharge enriched oxygen gas at a set flow rate; a control method; and a control program. Provided is an oxygen enrichment device that can, before a pressure equalization step, preliminarily start increasing the pressure of adsorption cylinders in which pressure has been reduced, thereby inhibiting a reduction in the pressure of both cylinders during the pressure equalization step and as a result inhibiting a reduction in the internal pressure of an enriched oxygen gas tank.
Provided are: an oxygen enrichment device that can inhibit a reduction in the internal pressure of an enriched oxygen gas tank in order to discharge enriched oxygen gas at a set flow rate; a control method; and a control program. Provided is an oxygen enrichment device that can, before a pressure equalization step, preliminarily start increasing the pressure of adsorption cylinders in which pressure has been reduced, thereby inhibiting a reduction in the pressure of both cylinders during the pressure equalization step and as a result inhibiting a reduction in the internal pressure of an enriched oxygen gas tank.
Provided are: an oxygen concentration apparatus which can be prevented from the decrease in a pilot pressure in a supply flow path opening/closing part or a discharged gas flow path opening/closing part can be prevented, in which at least one of the supply flow path opening/closing part and the discharged gas flow path opening/closing part is a pilot-operated solenoid valve; a control method; and a control program. An oxygen concentration apparatus is provided, which is configured such that the application of a pressure to adsorption columns that have been decreased in pressure is started prior to a pressure equalization step, and therefore the decrease in pressure in both of the adsorption columns can be prevented during the pressure equalization step, resulting in the prevention of the decrease in pilot pressure in a supply flow path opening/closing part or a discharged gas flow path opening/closing part in which at least one of the supply flow path opening/closing part and the discharged gas flow path opening/closing part is a pilot-operated solenoid valve.
Provided are: an oxygen concentration apparatus which can be prevented from the decrease in a pilot pressure in a supply flow path opening/closing part or a discharged gas flow path opening/closing part can be prevented, in which at least one of the supply flow path opening/closing part and the discharged gas flow path opening/closing part is a pilot-operated solenoid valve; a control method; and a control program. An oxygen concentration apparatus is provided, which is configured such that the application of a pressure to adsorption columns that have been decreased in pressure is started prior to a pressure equalization step, and therefore the decrease in pressure in both of the adsorption columns can be prevented during the pressure equalization step, resulting in the prevention of the decrease in pilot pressure in a supply flow path opening/closing part or a discharged gas flow path opening/closing part in which at least one of the supply flow path opening/closing part and the discharged gas flow path opening/closing part is a pilot-operated solenoid valve.
Provided is a breathing apparatus that is equipped with an expiration closing valve that is provided with, in a respiration flow passage inside a housing, a valve body capable of being moved by the flow of expiration, and that closes an opening after a prescribed period of time has elapsed since the beginning of expiration. As a result, the breathing apparatus controls the timing for discharge of a user's expiration out of the system so as to maintain the internal pressure in an airway during expiration and to make the airway open.
A phototherapy device includes a laser light source 8 for emitting laser light toward a target portion, a body part 5, an intake port 12 provided at a side surface of the body part 5, a discharge port 13 provided at the side surface of the body part 5 at an opposite side from the intake port 12, and an air supply device 14 for supplying air to be ejected from the intake port 12 to the inside of the body part 5, the intake port 12 configured so that an ejection direction F0 of the air is toward the near side from a center of an emission area A of the laser light at the target portion T.
Disclosed is a cell culture device that has advantages of preventing deformation of the culture device during operations for taking-in/out of cells and changing a medium and preventing an increase in the carbon dioxide concentration and a decrease in the medium pH over time during cell culture. Also disclosed is a parallel filter connector for assembling the cell culture device. This cell culture device is provided with two different kinds of filters which are disposed in parallel and each demarcate between the inner gas phase of the cell culture device and the outside air. The parallel filter connector for assembling the cell culture device has an opening connected to the main body of the cell culture device and two openings to which the two different types of filters can be respectively provided.
The present invention provides compounds which inhibit the activity of TRPC6, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
In order to provide a transcranial magnetic stimulator device which enables delivery of a magnetic stimulus at a required strength level in the brain even when current values and voltage values applied to magnetic stimulation coils in multiple resonance circuits are kept low, this transcranial magnetic stimulator device is configured to comprise: a plurality of resonance circuits (21, 22) for generating variable magnetic fields by applying pulse currents to a plurality of magnetic stimulation coils (11, 12); and an electric power source (3) for supplying electric power to the resonance circuits. The stimulator device is also configured such that: the resonance circuits (21, 22) are connected in parallel to the electric power source (3), and as such, the magnetic stimulation coils (11, 12) are also connected in parallel to the electric power source (3); and the magnetic stimulation coils (11, 12) are formed in substantially the same shape and are disposed adjacent to each other so that magnetic fluxes generated as a result of application of the pulse currents will be oriented in the same direction.
In order to provide a transcranial magnetic stimulator device which enables delivery of a magnetic stimulus at a required strength level in the brain even when current values and voltage values applied to magnetic stimulation coils in multiple resonance circuits are kept low, this transcranial magnetic stimulator device is configured to comprise: a plurality of resonance circuits (21, 22) for generating variable magnetic fields by applying pulse currents to a plurality of magnetic stimulation coils (11, 12); and an electric power source (3) for supplying electric power to the resonance circuits. The stimulator device is also configured such that: the resonance circuits (21, 22) are connected in parallel to the electric power source (3), and as such, the magnetic stimulation coils (11, 12) are also connected in parallel to the electric power source (3); and the magnetic stimulation coils (11, 12) are formed in substantially the same shape and are disposed adjacent to each other so that magnetic fluxes generated as a result of application of the pulse currents will be oriented in the same direction.
The purpose of the present invention is to provide a phototherapeutic apparatus with which it is possible to accurately position a light irradiation region on a treatment site. A phototherapeutic apparatus according to one embodiment of the present invention is characterized by comprising: a lens barrel; a light source which is disposed within the lens barrel and which emits light; a plurality of imaging units which capture images of a marking placed on the body; a deviation amount calculation unit which calculates amounts of deviation between a plurality of marking images contained in the images captured by the imaging units; an image combining unit which combines the marking images on the basis of the calculated deviation amounts; a target position determination unit which, on a combined image, determines the position of a target that corresponds to a region to be irradiated with light from the light source; and a display unit which displays an image of the target so as to be superimposed on the combined marking image.
The purpose of the present invention is to provide a phototherapeutic apparatus with which it is possible to accurately position a light irradiation region on a treatment site. A phototherapeutic apparatus according to one embodiment of the present invention is characterized by comprising: a lens barrel; a light source which is disposed within the lens barrel and which emits light; a plurality of imaging units which capture images of a marking placed on the body; a deviation amount calculation unit which calculates amounts of deviation between a plurality of marking images contained in the images captured by the imaging units; an image combining unit which combines the marking images on the basis of the calculated deviation amounts; a target position determination unit which, on a combined image, determines the position of a target that corresponds to a region to be irradiated with light from the light source; and a display unit which displays an image of the target so as to be superimposed on the combined marking image.
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof.?Specifically provided is a vitamin D derivative represented by formula (1), or a pharmaceutically acceptable salt or a solvate thereof.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 207/10 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 211/48 - Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 265/34 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a pharmaceutically acceptable salt or a solvate thereof.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 207/10 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 211/48 - Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 265/34 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Provided is a respiratory monitoring device that measures and outputs the substantial use time of an oxygen supply device. A respiratory monitoring device (4) used in combination with an oxygen supply device (1) delivering highly concentrated oxygen gas includes a detection unit (6) that detects a change in breathing-related information representing at least one of a pressure, a flow rate, and a gas temperature, based on exhalation and inhalation, a calculation unit (725) that calculates a respiratory rate, based on the change in breathing-related information, a determination unit (726) that determines whether breathing is present, and whether a user of the oxygen supply device is present, based on the respiratory rate, a measurement unit (727) that measures a duration in which a user of an oxygen supply device has been determined to be present, based on a determination result obtained by the determination unit, and an output unit (728) that outputs a cumulative measurement result for the duration.
Provided is a respiratory rate measurement device (4), the respiratory rate measurement device (4) including a detection unit (6) that detects an in-tube pressure and/or an in-tube gas flow rate in a tube (2) supplying concentrated oxygen gas to a patient from a pressure swing adsorption oxygen concentration device (1) connected to the patient and concentrating oxygen in the air by periodically repeating pressurization and depressurization, and outputs pressure data and/or gas flow rate data, an arithmetic operation unit (722) that extracts patient respiratory information data, based on the pressure data and/or the gas flow rate data, and an estimation unit (723) that estimates a respiratory rate per predetermined time, based on the patient respiratory information data, wherein the estimation unit (723) estimates the respiratory rate using, as a respiratory interval, a time Δt in which the autocorrelation coefficient takes a peak.
Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.
The purpose of the present invention is to provide a new indication for light beam therapy or prophylaxis, and provide a new device for therapy or prophylaxis of irritable bowel syndrome. The light beam irradiation apparatus according to the present invention is for therapy or prophylaxis of irritable bowel syndrome, and realizes the therapy or prophylaxis of irritable bowel syndrome through transdermal irradiation, with a light beam, of sacral foramen on one side or both sides and the vicinities thereof.
The purpose of the present invention is to provide a new indication for light beam therapy or prophylaxis, and provide a new device for therapy or prophylaxis of irritable bowel syndrome. The light beam irradiation apparatus according to the present invention is for therapy or prophylaxis of irritable bowel syndrome, and realizes the therapy or prophylaxis of irritable bowel syndrome through transdermal irradiation, with a light beam, of sacral foramen on one side or both sides and the vicinities thereof.
The present invention is an apparatus that gives patency to the respiratory tract to reduce suffocating feeling by maintaining a pressure higher than atmospheric pressure in the nasopharynx during exhalation; an apparatus that is equipped with an air flow part communicating with a nasal mask covering user's nostrils or with user's nostrils and a casing forming a chamber for temporarily holding the exhaled air of the user; and provides a breathing apparatus that is equipped with a first opening provided in the casing for discharging the exhaled air temporarily held in the casing to the outside and an exhalation control valve that releases exhaled air to the first opening side at the start of exhalation of the user and closes the first opening when the pressure in the chamber on the nostril side exceeds a predetermined value due to exhalation.
Provided is an oxygen concentration device, a control method, and a control program with which a start-up interval until a desired high-concentration oxygen gas can be supplied can be reduced. The oxygen concentration device includes a pressurized air supply unit for supplying pressurized air, an adsorption tube which concentrates oxygen in the pressurized air by adsorbing nitrogen in the supplied pressurized air to generate oxygen gas, an oxygen gas tank for storing oxygen gas, a flow rate adjustment unit which adjusts an oxygen gas flow rate to be output to the exterior from the oxygen gas tank, and a control unit which controls the flow rate adjustment unit so that the oxygen gas flow rate becomes a set flow rate and controls the pressurized air supply unit so that the pressurized air achieves a supply amount corresponding to the set flow rate.
A61M 16/10 - Preparation of respiratory gases or vapours
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
In order to acquire patient respiratory information during oxygen concentrator operation, it is necessary to separate patient respiration components and variable pressure components associated with PSA from the measured data of the patient respiration pressure. Provided is a respiratory information acquisition device which acquires respiratory information of a patient and which is used fora PSA-type oxygen concentrator, including a pressure detection unit for detecting pressure in conduit and/or a flow rate detection unit for detecting a gas flow rate in the conduit, and a calculation unit for extracting oxygen respiratory information from detected pressure data and/or flow rate data, wherein the calculation unit estimates a fluctuation component which does not depend on respiration of the patient based on detected data and information related to an operation state of the oxygen concentrator obtained from the oxygen concentrator, and extracts respiratory information by removing the fluctuation component estimated from the detected pressure data and/or the flow rate data.
A nitric oxide administration device 14 includes a second flow path 201 including an intake port 201a and an NO supply port 201b, a discharge unit 205 which is arranged in the second flow path 201 and which generates NO from air introduced via the intake port 201a, generated NO being supplied via the NO supply port 201b, an NO2 adsorption unit 206 which is arranged downstream of the discharge unit 205 and removes NO2, a bypass flow path 217 for reflux from downstream of the NO2 adsorption unit 206 to upstream of the NO2 adsorption unit 206, and a three-way valve 216 for switching the opening and closing of a flow path from downstream of the NO2 adsorption unit 206 to the NO supply port 201b.
Provided are: an anti-IGF-1 receptor humanized antibody which includes CDRs of a light chain and a heavy chain derived from mice parent antibody IGF11-16, and respective FRs of a light chain and a heavy chain derived from a human antibody, and in which at least one of the CDRs includes at least one amino acid residue substitution with respect to a corresponding CDR of the mice parent antibody; a fragment of the anti-IGF-1 receptor humanized antibody; or a derivative thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
Provided are: an anti-IGF-1 receptor humanized antibody which includes CDRs of a light chain and a heavy chain derived from mice parent antibody IGF11-16, and respective FRs of a light chain and a heavy chain derived from a human antibody, and in which at least one of the CDRs includes at least one amino acid residue substitution with respect to a corresponding CDR of the mice parent antibody; a fragment of the anti-IGF-1 receptor humanized antibody; or a derivative thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A relay administration device 50 for use in connection to a nitric oxide administration device 20 which supplies NO generated from air, includes an NO densitometer 506, a flowmeter 507 or pressure gauge 504, a control unit 600 which calculates a dosage of NO to be administered to a patient based on an NO concentration measured by the NO densitometer 506 and a value of the flowmeter 507 or the pressure gauge 504, and a two-way valve 505 which is configured to increase a flow rate when the calculated dosage is less than a predetermined value and to decrease the flow rate when the calculated dosage is greater than a predetermined value.
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1–X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.)
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1?X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.)
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A nitric oxide administration device 25 includes a second flow path 201 including an intake port 201a and an NO supply port 201b, a discharge unit 205 which is arranged in the second flow path 201 and which generates NO from air introduced via the intake port 201a, generated NO being supplied via the NO supply port 201b, an NO2 adsorption unit 206 which is arranged downstream of the discharge unit 205 and which removes NO2, an NO densitometer 208 which is arranged downstream of the discharge unit 205 or which is arranged in a flow path for reflux from downstream of the NO2 adsorption unit 206 to upstream of the NO2 adsorption unit 206, and a concentration estimation unit 301 which estimates an NO concentration and an NO2 concentration in a predetermined position based on an oxygen concentration in the atmosphere or the second flow path 201, an NO concentration measured by the NO densitometer 208, and a residence time of gas containing NO in the second flow path 201 between the NO2 adsorption unit 206 and the predetermined position.
Provided is an oxygen concentration device which can reduce force in the detachment direction acting on a cartridge-type adsorption cylinder from an oxygen concentrator body, ensure connection with an oxygen concentration device, and make it possible to easily and reliably perform exchange work such as attachment and detachment of the adsorption cylinder, the oxygen concentration device being characterized in that an axial line, which is a gas flow direction of the adsorption cylinder, and a connection shaft of either of a pressurized air supply end to the adsorption cylinder or an oxygen extraction end from the adsorption cylinder intersect with each other.
Provided is an oxygen concentration device which can reduce force in the detachment direction acting on a cartridge-type adsorption cylinder from an oxygen concentrator body, ensure connection with an oxygen concentration device, and make it possible to easily and reliably perform exchange work such as attachment and detachment of the adsorption cylinder, the oxygen concentration device being characterized in that an axial line, which is a gas flow direction of the adsorption cylinder, and a connection shaft of either of a pressurized air supply end to the adsorption cylinder or an oxygen extraction end from the adsorption cylinder intersect with each other.
A phototherapy apparatus comprising a laser light source 8 that irradiates a target site with a laser, a body part 5, an air intake opening 12 provided in a side surface of the body part 5, an air exhaust opening 13 provided in a side surface of the body part 5 so as to be on the opposite side from the air intake opening 12, and an air supply device 14 that supplies air jetted from the air intake opening 12 into the body part 5, the air intake opening 12 being configured so that the jetting direction F0 of the air faces forward relative to the center of a laser irradiation field A on the target site T.
A61N 5/067 - Radiation therapy using light using laser light
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A phototherapy apparatus comprising a laser light source 8 that irradiates a target site with a laser, a body part 5, an air intake opening 12 provided in a side surface of the body part 5, an air exhaust opening 13 provided in a side surface of the body part 5 so as to be on the opposite side from the air intake opening 12, and an air supply device 14 that supplies air jetted from the air intake opening 12 into the body part 5, the air intake opening 12 being configured so that the jetting direction F0 of the air faces forward relative to the center of a laser irradiation field A on the target site T.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A61N 5/067 - Radiation therapy using light using laser light
5050) for the signal of at least one ligand from among three human IL-36R agonist ligands IL-36α, IL-36β and IL-36γ than the half maximal inhibitory concentration for the signal of at least one of the other ligands.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A medical dressing containing tannin and a specific oxygen-atom-containing polymer. Because a state in which a gel-form film is formed can be maintained for a long time even in the moist environment that is expected within a body, this medical dressing is suitable for the treatment of ulcers, etc., that occur after endoscopic submucosal dissection, and for hemostasis of the gastrointestinal tract.
A61L 15/20 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
A61L 15/24 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bondsDerivatives thereof
A61L 15/26 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bondsDerivatives thereof
An oxygen generator comprising: a first battery that generates, by an oxygen reduction reaction, an active material for an oxygen generation reaction; a second battery that generates oxygen by the oxygen generation reaction; an electricity storage device that is charged by electric charge generated by the first battery, and, when the second battery generates oxygen, discharges and supplies electric charge to the second battery; a switching circuit that performs switching between a first path that connects the first battery and the electricity storage device and a second path that connects the second battery and the electricity storage device; and a control device that controls the switching between the first path and the second path.
Provided is a breathing apparatus as an apparatus which can reduce the exhalation of an expired gas in a later stage of breathing using an elastic film, can apply a high pressure to a nasopharyngeal region to allow the airway to be patent, and is reduced in harsh flow noise, the breathing apparatus being equipped with a nose mask that covers a nasal aperture region in a user or an air flowing part that communicates with the nasal aperture region, and a housing that forms a chamber in which an expired gas from the user is stored temporality, the breathing apparatus being characterized by being equipped with an opening part through which the expired gas stored temporality in the housing is released to the outside and an expired gas control valve which is so configured that the expired gas is released on the opening part side at the start of breathing of the user and is closed when the pressure in a chamber on the nasal aperture region side reaches a predetermined value or more due to by the action of the expired gas, wherein the expired gas control valve is equipped with a plurality of elastic films each of which has pores through which the expired gas can flow and a wall surface part which is so configured that the elastic films come into contact with pore edges of the pores as the result of the pressure deformation of the elastic films toward the opening part side to close the opening of the pores when the pressure in the inside of the chamber on the nasal aperture region side reaches a predetermined value or more.
Provided is a respiratory apparatus whereby the airway is given patency by a pressure higher than atmospheric pressure being applied to the upper pharynx during exhalation, thereby reducing dyspnea. The respiratory apparatus is characterized by: being provided with a ventilation part communicating with the nostril of a user or a nasal mask for covering the nostril, a casing for forming a chamber for temporarily retaining exhaled air from the user, and an opening for discharging the exhaled air temporarily retained in the casing to the outside; comprising, before the opening within the casing, an exhaled air control valve provided with an elastic body that is pressure-deformable and has a hole through which exhaled air passes and with a wall surface part that makes contact with the rim of the hole when the elastic body is deformed by pressure toward the opening, thereby stopping the flow of exhaled air; and comprising a conductive part on at least the wall surface side of the elastic body and an electrode on the surface of the wall surface part which makes contact with the elastic body.
The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An oxygen therapy system receives data for an elapsed time such as a flow rate of oxygen gas, and a blood oxygen level or a carbon dioxide partial pressure in arterial blood (PaCO2) level of a user, from an oxygen supply device, calculates a proportion of a duration for each oxygen gas flow rate during which the blood oxygen level or PaCO2 is in a prescribed range from the acquired data in which the oxygen gas flow rate fluctuates with the blood oxygen level or carbon dioxide partial pressure in arterial blood (PaCO2), and displays the calculated data as a histogram or pie graph on a terminal which a healthcare worker such as a physician operates.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61M 16/10 - Preparation of respiratory gases or vapours
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
73.
PHOTOTHERAPY DEVICE AND METHOD OF OPERATION OF PHOTOTHERAPY DEVICE
A light therapy device 1 is structured so as to comprise: a laser light source 8 that irradiates a target location T with a laser; a limit switch 10 that detects that the laser light source 8 has approached a prescribed distance with regard to the target location T, and outputs a proximity signal; and an optical sensor 7 that detects the distance to the target location T and outputs a distance signal S corresponding to said distance, wherein after the proximity signal has been detected, a reference value L0 is set on the basis of the detected distance signal S, and the laser irradiation by the laser light source 8 is allowed in accordance with the amount of variation in the distance signal S with regard to the reference value L0.
A light therapy device 1 is structured so as to comprise: a laser light source 8 that irradiates a target location T with a laser; a limit switch 10 that detects that the laser light source 8 has approached a prescribed distance with regard to the target location T, and outputs a proximity signal; and an optical sensor 7 that detects the distance to the target location T and outputs a distance signal S corresponding to said distance, wherein after the proximity signal has been detected, a reference value L0 is set on the basis of the detected distance signal S, and the laser irradiation by the laser light source 8 is allowed in accordance with the amount of variation in the distance signal S with regard to the reference value L0.
The purpose of the present invention is to provide a therapeutic or prophylactic agent for fibromyalgia, which contains oxytocin as an active ingredient. Provided by the present invention is a therapeutic or prophylactic agent that is for fibromyalgia and that contains oxytocin as an active ingredient. Administration of 1-500 U/body of oxytocin alone or in combination with pregabalin provides a therapeutic or prophylactic effect against fibromyalgia.
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
76.
BREATHING STATE DETECTION APPARATUS, BREATHING STATE DETECTION METHOD, AND BREATHING STATE DETECTION PROGRAM
Provided are a device, method, and program whereby recruitment of accessory muscles of respiration, which is characteristic of labored breathing, in a non-medical professional at home or the like is easily detected and objectively expressed. A region including accessory muscles of respiration is extracted from a moving image including the neck of a person, and a morphological feature within the region is extracted. Whether the extracted morphological feature is derived from breathing or not is determined, and if the feature is derived from breathing, an index indicating a breathing state is calculated on the basis of a change in the morphological feature.
Disclosed herein are compounds which inhibit the activity of TRPC6, pharmaceutically acceptable salts thereof, phainiaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. The compounds may be synthesized by the general scheme:
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention provides a breathing apparatus as an apparatus whereby an airway is given patency by maintaining a higher-than-atmospheric pressure in the upper pharynx during exhalation, and dyspnea is reduced, the apparatus comprising a ventilation part communicated with a nostril part or a nasal mask for covering a nostril part of a user, and a casing for forming a chamber for temporarily retaining exhaled air from the user, the breathing apparatus comprising a first opening provided in the casing, for discharging the exhaled air temporarily retained in the casing to the outside, and an exhalation control valve for closing the first opening when exhaled air is released toward the first opening at the start of exhalation by the user, and the pressure of an in-chamber part on the nostril-part side is made equal to or greater than a predetermined value by the exhalation.
The present invention provides a breathing apparatus as an apparatus whereby an airway is given patency by maintaining a higher-than-atmospheric pressure in the upper pharynx during exhalation, and dyspnea is reduced, the apparatus comprising a ventilation part communicated with a nostril part or a nasal mask for covering a nostril part of a user, and a casing for forming a chamber for temporarily retaining exhaled air from the user, the breathing apparatus comprising a first opening provided in the casing, for discharging the exhaled air temporarily retained in the casing to the outside, and an exhalation control valve for closing the first opening when exhaled air is released toward the first opening at the start of exhalation by the user, and the pressure of an in-chamber part on the nostril-part side is made equal to or greater than a predetermined value by the exhalation.
Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides an oxygen concentration device, comprising: a pressurized air supply unit for supplying pressurized air, an adsorption tube to which pressurized air is supplied from the pressurized air supply unit and which concentrates oxygen in the pressurized air, an oxygen gas tank, a flow rate adjustment unit, and a control unit which controls the flow rate adjustment unit, wherein the control unit, only in a start-up interval of the oxygen concentration device, controls the flow rate adjustment unit, and controls the pressurized air supply unit, wherein the oxygen concentration device further comprising an end of start-up process determination unit, wherein, when a determination of the end of the start-process is made, the control unit control to reduces the start supply amount to the set supply amount and to reduces the start flow rate to the set flow rate within 10 seconds from the determination.
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
A61M 16/10 - Preparation of respiratory gases or vapours
84.
OXYGEN CONCENTRATOR, CONTROL METHOD, AND CONTROL PROGRAM
The purpose of the invention is to provide an oxygen concentrator, a control method, and a control program that can shorten the startup period until a desired high concentration oxygen gas can be supplied. Provided is an oxygen concentrator that has a pressurized air supply unit to supply pressurized air, an adsorption pipe to generate oxygen gas by adsorbing the nitrogen in the pressurized air and concentrating the oxygen in the pressurized air, an oxygen gas tank to store the oxygen gas, a flow rate regulator to regulate the flow rate of oxygen gas output from the oxygen gas tank to the outside, and a control unit to control the flow rate regulator so that the oxygen gas flow rate is a set flow rate and to control the pressurized air supply unit so that the pressurized air is at a supply rate according to the set flow rate, wherein the control unit controls the flow rate regulator so that the oxygen gas flow rate has a startup flow rate equal to or greater than the set flow rate only during the oxygen concentrator startup period and controls the pressurized air supply unit so that the pressurized air has a startup supply rate equal to or greater than the set supply rate according to the respective set flow rates.
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
A61M 16/10 - Preparation of respiratory gases or vapours
85.
Exacerbation predicting device, oxygen concentrating device, and exacerbation predicting system
Provided is an exacerbation prediction device equipped with a respiration sensing means of continuously sensing respiration data of a patient, a calculation means of calculating stable respiration data that are respiration data during a condition in which a respiratory rate is lowered and stable for a certain period of time from the sensed continuous respiration data of the patient, and a prediction means of predicting occurrence of an acute exacerbation in the patient in accordance with the stable respiration data calculated during a certain period of time.
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 16/10 - Preparation of respiratory gases or vapours
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
This nitric oxide administration device 25 comprises: a second flow path 201 having an air suction port 201a and an NO supply port 201b; an electric discharge unit 205 disposed in the second flow path 201, for generating NO from the air that has flowed in through the air suction port 201a, and wherefrom the generated NO is supplied via the NO supply port 201b; an NO2 adsorption unit 206 disposed downstream from the electric discharge unit 205, for eliminating NO2; an NO concentration meter 208 disposed downstream from the electric discharge unit 205 or disposed in a flow path that circulates gas from downstream of the NO2 adsorption unit 206 to upstream of the NO2 adsorption unit 206; and a concentration estimation unit 301 estimating the NO concentration and the NO2 concentration at a predetermined position on the basis of the oxygen concentration in the atmosphere or in the second flow path 201, the NO concentration measured by the NO concentration meter 208, and the retention time of an NO-containing gas in the second flow path 201 between the NO2 adsorption unit 206 and the predetermined position.
A nitric oxide administration device 1 comprises: a first flow channel 101 provided with a first intake port 101a and an oxygen supply port 101b; an oxygen generating unit 100 which is disposed in the first flow channel 101 and which generates concentrated oxygen from air flowing in via the first intake port 101a, the concentrated oxygen generated by the oxygen generating unit 100 being supplied via the oxygen supply port 101b; a second flow channel 201 which branches from the first flow channel 101 and is provided with an NO supply port 201b; and an NO generating unit 200 which is disposed in the second flow channel 201 and which generates NO from a gas distributed from the first flow channel 101, the NO generated by the NO generating unit 200 being supplied via the NO supply port 201b.
A nitric oxide administration device 14 comprises: a second flow channel 201 provided with an intake port 201a and an NO supply port 201b; an electric discharge unit 205 which is disposed in the second flow channel 201 and which generates NO from air flowing in via the second intake port 201a, the NO generated by the electric discharge unit 205 being supplied via the NO supply port 201b; an NO2 adsorption unit 206 which is disposed downstream from the electric discharge unit 205 and which removes NO2; a bypass flow channel 217 for returning from downstream of the NO2 adsorption unit 206 to upstream of the NO2 adsorption unit 206; and a three-way valve 216 for switching the opening and closing of a flow channel from downstream of the NO2 adsorption unit 206 to the NO supply port 201b.
A relay administration device 50 that is connected to a nitrogen monoxide administration device 20 which supplies NO that is generated from air includes: an NO densitometer 506; a flowmeter 507 or a pressure gauge 504; a control unit 600 that calculates an NO dose to be administered to a patient on the basis of NO density measured by the NO densitometer 506 and the value of the flowmeter 507 or the pressure gauge 504; and a two way valve 505 that is configured to increase the flow rate when the calculated dose is less than a predetermined value, and reduce the flow rate when the calculated dose is more than the predetermined value.
A relay administration device 50 that is connected to a nitrogen monoxide administration device 20 which supplies NO that is generated from air includes: an NO densitometer 506; a flowmeter 507 or a pressure gauge 504; a control unit 600 that calculates an NO dose to be administered to a patient on the basis of NO density measured by the NO densitometer 506 and the value of the flowmeter 507 or the pressure gauge 504; and a two way valve 505 that is configured to increase the flow rate when the calculated dose is less than a predetermined value, and reduce the flow rate when the calculated dose is more than the predetermined value.
A nitric oxide administration device 1 comprises: a first flow channel 101 provided with a first intake port 101a and an oxygen supply port 101b; an oxygen generating unit 100 which is disposed in the first flow channel 101 and which generates concentrated oxygen from air flowing in via the first intake port 101a, the concentrated oxygen generated by the oxygen generating unit 100 being supplied via the oxygen supply port 101b; a second flow channel 201 which branches from the first flow channel 101 and is provided with an NO supply port 201b; and an NO generating unit 200 which is disposed in the second flow channel 201 and which generates NO from a gas distributed from the first flow channel 101, the NO generated by the NO generating unit 200 being supplied via the NO supply port 201b.
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A01K 67/027 - New or modified breeds of vertebrates
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
In order to acquire breathing information of a patient during operation of an oxygen concentrating device, a patient breathing component and a pressure fluctuation component accompanying PSA must be isolated from data obtained by measuring the breathing pressure of the patient. A breathing information acquisition device for acquiring breathing information of a patient used in a PSA-type oxygen concentrating device, wherein the breathing information acquisition device is characterized by having: a pressure sensing unit for sensing the pressure in piping, and/or a flow rate sensing unit for sensing the flow rate of air in the piping; and a computation unit for extracting patient breathing information from sensed pressure data and/or flow rate data; the computation unit extracting the breathing information by estimating a fluctuation component not due to breathing of the patient on the basis of the sensed data and information relating to the operating state of the oxygen concentrating device, obtained from the oxygen concentrating device, and removing a fluctuation component estimated from the sensed pressure data and/or flow rate data.
In order to acquire breathing information of a patient during operation of an oxygen concentrating device, a patient breathing component and a pressure fluctuation component accompanying PSA must be isolated from data obtained by measuring the breathing pressure of the patient. A breathing information acquisition device for acquiring breathing information of a patient used in a PSA-type oxygen concentrating device, wherein the breathing information acquisition device is characterized by having: a pressure sensing unit for sensing the pressure in piping, and/or a flow rate sensing unit for sensing the flow rate of air in the piping; and a computation unit for extracting patient breathing information from sensed pressure data and/or flow rate data; the computation unit extracting the breathing information by estimating a fluctuation component not due to breathing of the patient on the basis of the sensed data and information relating to the operating state of the oxygen concentrating device, obtained from the oxygen concentrating device, and removing a fluctuation component estimated from the sensed pressure data and/or flow rate data.
Provided is a respiration rate measurement device (4) used for a PSA-type oxygen concentration device and capable of improving measurement precision, characterized in that the measurement device comprises a sensing unit (6) which is connected to a patient and which senses an intra-tubal pressure and/or an intra-tubal air flow rate in a tube (2) which supplies concentrated oxygen gas to the patient from a pressure swing adsorption-type oxygen concentration device (1) that concentrates oxygen in air by periodic repetition of pressurization and depressurization, and which outputs pressure data and/or air flow rate data, a computation unit (722) which extracts patient respiration information data on the basis of the pressure data and/or the air flow rate data, and an estimation unit (723) which estimates a respiration rate per prescribed unit time on the basis of the patient respiration information data, where the estimation unit (723) derives an autocorrelation coefficient between the patient respiration information data and data which is shifted from the patient respiration information data by a time Δt while adjusting said time Δt, and estimates the respiration rate using the time Δt at which the autocorrelation coefficient reaches a peak as a respiration interval.
Provided is a respiration monitoring device which measures an effective use time of an oxygen supply device and carries out an output. This respiration monitoring device (4) is used together with an oxygen supply device (1) which transmits a highly-concentrated oxygen gas, and is characterized by comprising: a sensing unit (6) which senses a inhalation and exhalation-based change in information that is related to at least one of pressure, flow rate, or gas temperature and associated with respiration; a computation unit (725) which carries out a computation of a respiration rate on the basis of the change in the information associated with respiration; a determination unit (726) which determines whether respiration is taking place and whether a user of the oxygen supply device is present on the basis of the respiration rate; a measurement unit (727) which, on the basis of the result of the determination by the determination unit, measures a period in which it is determined that the user of the oxygen supply device is present; and an output unit (728) which outputs a cumulative measurement result for the period.
The oxygen supply device supplying a user with an oxygen gas for inhalation comprises: a first sensor unit acquiring information on percutaneous arterial oxygen saturation (SpO2) of the user, a second sensor unit acquiring information on respiratory frequency per minute (BPM), and a control unit. Under the condition where the SpO2 level acquired by the first sensor unit is equal to or larger than the predetermined first threshold and the BPM value acquired by second sensor unit is equal to or larger than the predetermined second threshold, the control unit regards the condition as a possible sign of CO2 narcosis that exhibits an increase in PaCO2 level, and thus judges the condition as an abnormal sign. Then the control unit executes controls such as stopping supply of the oxygen gas to the user, and the like.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61B 5/08 - Measuring devices for evaluating the respiratory organs
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
100.
Respiratory information acquisition device and respiratory information acquisition method
A respiratory information acquisition device used for a PSA type oxygen concentration device that switches and uses multiple adsorption cylinders includes a respiratory information acquisition means of measuring a first pressure of a periodic pressure fluctuation in an oxygen supply path when oxygen is supplied to a patient from the PSA type oxygen concentration device and a second pressure of a periodic pressure fluctuation in the oxygen supply path when oxygen is not supplied to the patient from the PSA type oxygen concentration device, a phase confirmation means of matching phases of the first pressure and the second pressure, and a subtraction processing means of calculating a difference between the first pressure and the second pressure in the condition where the phases are matched.
